# Arrowhead Pharmaceuticals (ARWR) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ARWR
## Company Profile
- Ticker: ARWR
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Rare Disease
## Stock Data
- Close: 87.25 USD
- Market cap: 9975494227.22 USD
- Last updated: 2026-08-12
## Business Overview
### RNA Interference Platform
Arrowhead Pharmaceuticals develops RNA interference medicines that silence disease-causing genes. Its delivery technologies support programs targeting the liver and other tissues.
### REDEMPLO
REDEMPLO, or plozasiran, is an RNAi therapy targeting APOC3. It is approved in the United States to reduce triglycerides in adults with familial chylomicronemia syndrome and is under review in additional regions.
### Dual-Target Cardiometabolic RNAi
ARO-DIMER-PA is a dual-functional RNAi candidate designed to silence both PCSK9 and APOC3 in a single molecule for atherosclerotic cardiovascular disease associated with mixed hyperlipidemia.
### Obesity Programs
ARO-INHBE and ARO-ALK7 are RNAi candidates targeting adipose biology. Early clinical development is assessing effects on weight loss and body composition in people with obesity.
### Liver-Disease and Partnered Pipeline
ARO-PNPLA3 targets a genetically defined form of liver disease and is partnered with Madrigal. Arrowhead also advances programs across pulmonary, neuromuscular and other tissues using its TRiM platform.
## Why The Stock Is Moving

As of Aug 12, 2026, ARWR closed down 2.23% at $87.25. No new same-company headline was identified in the current news window.

## Future Catalysts

- European Commission decision on marketing authorization for REDEMPLO in the second quarter of 2026.

## Recent News
- 2026-08-04 20:01 EST — [Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results](https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-reports-fiscal-2026-third-quarter-results-04a63b64) — Source: Arrowhead Pharmaceuticals
- 2026-08-04 20:00 EST — [Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher](https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-acquires-fda-priority-review-voucher-4a0417b4) — Source: Arrowhead Pharmaceuticals
- 2026-08-03 20:30 EST — [Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-56-a75d3369) — Source: Arrowhead Pharmaceuticals
- 2026-07-27 11:30 EST — [Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia](https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-completes-enrollment-in-global-phase-3-yosemite-study--adc124af) — Source: Arrowhead Pharmaceuticals
- 2026-07-22 11:30 EST — [Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia](https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-reports-topline-results-from-phase-3-shasta-3-and-shas-fca7dc05) — Source: Arrowhead Pharmaceuticals